Page 14 - 南京医科大学学报自然科学版
P. 14
第42卷第10期
·1356 · 南 京 医 科 大 学 学 报 2022年10月
logica,2018,103(9):e404-e407 chemotherapeutic effects of doxorubicin[J]. Nat Com⁃
[14] DINARDO C D,JONAS B A,PULLARKAT V,et al. mun,2013,4:1908
Azacitidine and venetoclax in previously untreated acute [23] QIAO X H,VAN DER ZANDEN S Y,WANDER D P A,
myeloid leukemia[J]. N Engl J Med,2020,383(7):617- et al.Uncoupling DNA damage from chromatin damage to
629 detoxify doxorubicin[J]. PNAS,2020,117(26):15182-
[15] DINARDO C D,PRATZ K,PULLARKAT V,et al. Vene⁃ 15192
toclax combined with decitabine or azacitidine in treat⁃ [24] IIHOSHI H,ISHIHARA T,KURODA S,et al. Aclarubi⁃
ment⁃naive,elderly patients with acute myeloid leukemia cin,an anthracycline anti⁃cancer drug,fluorescently con⁃
[J]. Blood,2019,133(1):7-17 trasts mitochondria and reduces the oxygen consumption
[16] MAITI A,DINARDO C D,QIAO W,et al. Ten ⁃ day rate in living human cells[J]. Toxicol Lett,2017,277:
decitabine with venetoclax versus intensive chemotherapy 109-114
in relapsed or refractory acute myeloid leukemia:a pro⁃ [25] FANDY T E,JIEMJIT A,THAKAR M,et al. Decitabine
pensity score ⁃ matched analysis[J]. Cancer,2021,127 induces delayed reactive oxygen species(ROS)accumu⁃
(22):4213-4220 lation in leukemia cells and induces the expression of
[17] SONG B Q,WANG X,KONG X,et al. Clinical response ROS generating enzymes[J]. Clin Cancer Res,2014,20
to venetoclax and decitabine in acute promyelocytic leu⁃ (5):1249-1258
kemia with a novel RARA⁃THRAP3 fusion:a case report [26] LI L Z,LIU W J,SUN Q,et al. Decitabine downregulates
[J]. Front Oncol,2022,12:828852 TIGAR to induce apoptosis and autophagy in myeloid leu⁃
[18] LIU M,ZHAO X J,PAN W J,et al. A novel HNRNPC⁃ kemia cells[J]. Oxidative Med Cell Longev,2021,2021:
RARA fusion in acute promyelocytic leukaemia lacking 8877460
PML⁃RARA rearrangement,sensitive to venetoclax⁃based [27] NGUYEN L X T,TROADEC E,KALVALA A,et al. The
therapy[J]. Br J Haematol,2021,195(2):e123-e128 Bcl⁃2 inhibitor venetoclax inhibits Nrf2 antioxidant path⁃
[19] LI Y L,YU J N,XU Q H,et al. Relapsed/refractory acute way activation induced by hypomethylating agents in AML
promyelocytic leukemia with RARA⁃LBD region mutation [J]. J Cell Physiol,2019,234(8):14040-14049
was salvaged by venetoclax:a case report[J]. Medicine, [28] NIU X,WANG G,WANG Y,et al. Acute myeloid leuke⁃
2021,100(48):28076 mia cells harboring MLL fusion genes or with the acute
[20] ESTELLER M. Epigenetics in cancer[J]. N Engl J Med, promyelocytic leukemia phenotype are sensitive to the Bcl⁃
2008,358(11):1148-1159 2⁃selective inhibitor ABT⁃ 199[J]. Leukemia,2014,28
[21] PALII S S,VAN EMBURGH B O,SANKPAL U T,et al. (7):1557-1560
DNA methylation inhibitor 5⁃Aza⁃2′⁃deoxycytidine induc⁃ [29] KONTRO M,KUMAR A,MAJUMDER M M,et al. HOX
es reversible genome⁃wide DNA damage that is distinctly gene expression predicts response to BCL⁃2 inhibition in
influenced by DNA methyltransferases 1 and 3B[J]. Mol acute myeloid leukemia[J]. Leukemia,2017,31(2):
Cell Biol,2008,28(2):752-771 301-309
[22] PANG B X,QIAO X H,JANSSEN L,et al. Drug⁃induced [收稿日期] 2022-04-17
histone eviction from open chromatin contributes to the (本文编辑:蒋 莉)